CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120.
Despite the therapeutic impact of anti-retroviral therapy, HIV-1-associated neurocognitive disorder (HAND) remains a serious threat to AIDS patients, and there currently remains no specific therapy for the neurological manifestations of HIV-1. Recent work suggests that the nigrostriatal dopaminergic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3798286?pdf=render |
| _version_ | 1818177201770594304 |
|---|---|
| author | Shuxian Hu Wen S Sheng R Bryan Rock |
| author_facet | Shuxian Hu Wen S Sheng R Bryan Rock |
| author_sort | Shuxian Hu |
| collection | DOAJ |
| description | Despite the therapeutic impact of anti-retroviral therapy, HIV-1-associated neurocognitive disorder (HAND) remains a serious threat to AIDS patients, and there currently remains no specific therapy for the neurological manifestations of HIV-1. Recent work suggests that the nigrostriatal dopaminergic area is a critical brain region for the neuronal dysfunction and death seen in HAND and that human dopaminergic neurons have a particular sensitivity to gp120-induced damage, manifested as reduced function (decreased dopamine uptake), morphological changes, and reduced viability. Synthetic cannabinoids inhibit HIV-1 expression in human microglia, suppress production of inflammatory mediators in human astrocytes, and there is substantial literature demonstrating the neuroprotective properties of cannabinoids in other neuropathogenic processes. Based on these data, experiments were designed to test the hypothesis that synthetic cannabinoids will protect dopaminergic neurons against the toxic effects of the HIV-1 protein gp120. Using a human mesencephalic neuronal/glial culture model, which contains dopaminergic neurons, microglia, and astrocytes, we were able to show that the CB1/CB2 agonist WIN55,212-2 blunts gp120-induced neuronal damage as measured by dopamine transporter function, apoptosis and lipid peroxidation; these actions were mediated principally by the CB2 receptor. Adding supplementary human microglia to our cultures enhances gp120-induced damage; WIN55,212-2 is able to alleviate this enhanced damage. Additionally, WIN55,212-2 inhibits gp120-induced superoxide production by purified human microglial cells, inhibits migration of human microglia towards supernatants generated from gp120-stimulated human mesencephalic neuronal/glial cultures and reduces chemokine and cytokine production from the human mesencephalic neuronal/glial cultures. These data suggest that synthetic cannabinoids are capable of protecting human dopaminergic neurons from gp120 in a variety of ways, acting principally through the CB2 receptors and microglia. |
| first_indexed | 2024-12-11T20:28:19Z |
| format | Article |
| id | doaj.art-eb9b402faba7409fb254fd58638a0a6a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T20:28:19Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-eb9b402faba7409fb254fd58638a0a6a2022-12-22T00:51:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7757710.1371/journal.pone.0077577CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120.Shuxian HuWen S ShengR Bryan RockDespite the therapeutic impact of anti-retroviral therapy, HIV-1-associated neurocognitive disorder (HAND) remains a serious threat to AIDS patients, and there currently remains no specific therapy for the neurological manifestations of HIV-1. Recent work suggests that the nigrostriatal dopaminergic area is a critical brain region for the neuronal dysfunction and death seen in HAND and that human dopaminergic neurons have a particular sensitivity to gp120-induced damage, manifested as reduced function (decreased dopamine uptake), morphological changes, and reduced viability. Synthetic cannabinoids inhibit HIV-1 expression in human microglia, suppress production of inflammatory mediators in human astrocytes, and there is substantial literature demonstrating the neuroprotective properties of cannabinoids in other neuropathogenic processes. Based on these data, experiments were designed to test the hypothesis that synthetic cannabinoids will protect dopaminergic neurons against the toxic effects of the HIV-1 protein gp120. Using a human mesencephalic neuronal/glial culture model, which contains dopaminergic neurons, microglia, and astrocytes, we were able to show that the CB1/CB2 agonist WIN55,212-2 blunts gp120-induced neuronal damage as measured by dopamine transporter function, apoptosis and lipid peroxidation; these actions were mediated principally by the CB2 receptor. Adding supplementary human microglia to our cultures enhances gp120-induced damage; WIN55,212-2 is able to alleviate this enhanced damage. Additionally, WIN55,212-2 inhibits gp120-induced superoxide production by purified human microglial cells, inhibits migration of human microglia towards supernatants generated from gp120-stimulated human mesencephalic neuronal/glial cultures and reduces chemokine and cytokine production from the human mesencephalic neuronal/glial cultures. These data suggest that synthetic cannabinoids are capable of protecting human dopaminergic neurons from gp120 in a variety of ways, acting principally through the CB2 receptors and microglia.http://europepmc.org/articles/PMC3798286?pdf=render |
| spellingShingle | Shuxian Hu Wen S Sheng R Bryan Rock CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. PLoS ONE |
| title | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| title_full | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| title_fullStr | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| title_full_unstemmed | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| title_short | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| title_sort | cb2 receptor agonists protect human dopaminergic neurons against damage from hiv 1 gp120 |
| url | http://europepmc.org/articles/PMC3798286?pdf=render |
| work_keys_str_mv | AT shuxianhu cb2receptoragonistsprotecthumandopaminergicneuronsagainstdamagefromhiv1gp120 AT wenssheng cb2receptoragonistsprotecthumandopaminergicneuronsagainstdamagefromhiv1gp120 AT rbryanrock cb2receptoragonistsprotecthumandopaminergicneuronsagainstdamagefromhiv1gp120 |